Tumour growth inhibition and anti-angiogenic effects using curcumin correspond to combined PDE2 and PDE4 inhibition

Thrombosis and Haemostasis

Volumn 113, Issue 2, 2015, Pages 319-328

  Abusnina, Abdurazzag ^a,b   Keravis, Thérèse ^a   Zhou, Qingwei ^a,c   Justiniano, Hélène ^a   Lobstein, Annelise ^a   Lugnier, Claire ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b UNIVERSITY OF TRIPOLI   (Libyan Arab Jamahiriya)

^c JILIN UNIVERSITY   (China)

Author keywords

Cyclic AMP; HUVEC; Melanoma cell; Tumour growth; VEGF

Indexed keywords

BAY 60 550; CURCUMIN; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 2; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 4; PHOSPHODIESTERASE INHIBITOR; ROLIPRAM; UNCLASSIFIED DRUG; VASCULOTROPIN; 2-(3,4-DIMETHOXYBENZYL)-7-(1-(1-HYDROXYETHYL)-4-PHENYLBUTYL)-5-METHYLIMIDAZO(5,1-F)(1,2,4)TRIAZIN-4 (3H)-ONE; ANGIOGENESIS INHIBITOR; IMIDAZOLE DERIVATIVE; PDE2A PROTEIN, HUMAN; PHOSPHODIESTERASE IV INHIBITOR; TRIAZINE DERIVATIVE; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CULTURE; CELL CYCLE PROGRESSION; CELL MIGRATION; CELL MIGRATION ASSAY; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYMATIC ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIO ENZYMATIC ASSAY; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CANCER TRANSPLANTATION; CELL CYCLE; CELL MOTION; CHEMISTRY; MELANOMA; METABOLISM; NEOPLASMS; PATHOLOGY; UMBILICAL VEIN ENDOTHELIAL CELL; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; CURCUMIN; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 2; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMIDAZOLES; MALE; MELANOMA; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOPLASMS; PHOSPHODIESTERASE 4 INHIBITORS; PHOSPHODIESTERASE INHIBITORS; ROLIPRAM; TRIAZINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 84922450469     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-05-0454     Document Type: Article

References (44)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med 1995; 1: 27-31.
2. Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000; 52: 237-268.
3. Granci V, Dupertuis YM, Pichard C. Angiogenesis as a potential target of pharmaconutrients in cancer therapy. Cur Opin Clin Nutr Metab Care 2010; 13: 417-422.
4. Ammon HP, Wahl MA. Pharmacology of Curcuma longa. Planta Med 1991; 57: 1-7.
5. Kunnumakkara AB, Anand P. Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signalling proteins. Cancer Lett 2008; 269: 199-225.
6. Zhou H, Beevers CS, Huang S. The targets of curcumin. Curr Drug Targets 2011; 12: 332-347.
7. Bengmark S, Mesa MD, Gil A. Plant-derived health: the effects of turmeric and curcuminoids. Nutr Hosp 2009; 24: 273-281.
8. Huang MT, Lou YR, Ma W, et al. Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res 1994; 54: 5841-5847.
9. Arbiser JL, Klauber N, Rohan R, et al. Curcumin is an in vivo inhibitor of angiogenesis. Mol Med 1998; 4: 376-383.
10. Schoeffter P, Lugnier C, Demesy-Waeldele F, et al. Role of cyclic AMP-and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. A study with selective inhibitors. Biochem Pharmacol 1987; 36: 3965-3972.
11. Houslay MD, Conti, M, Francis SH. The cyclic nucleotides. Handb Exp Pharmacol 2011; 204: v-vii.
12. Morgado M, Cairrão E, Santos-Silva AJ, Verde I. Cyclic nucleotide-dependent relaxation pathways in vascular smooth muscle. Cell Mol Life Sci 2012; 69: 247-266.
13. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006; 109: 366-398.
14. Omori K, Kotera J. Overview of PDEs and their regulation. Circ Res 2007; 100: 309-327.
15. Francis SH, Blount MA, Corbin JD. Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev 2011; 91: 651-690.
16. Keravis T, Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. Br J Pharmacol 2012; 165: 1288-1305.
17. Favot L, Keravis T, Lugnier C. VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors. Thromb Haemost 2003; 90: 334-343.
18. Favot L, Keravis T, Holl V, et al. Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4. Thromb Haemost 2004; 92: 634-645.
19. Abusnina A, Keravis T, Yougbaré I, et al. Anti-proliferative effect of curcumin on melanoma cells is mediated by PDE1A inhibition that regulates the epigenetic integrator UHRF1. Mol Nutr Food Res 2011; 55: 1677-1689.
20. Marivet MC, Bourguignon JJ, Lugnier C, et al. Inhibition of cyclic adenosine-3', 5'-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues. J Med Chem 1989; 32, 1450-1457.
21. Podzuweit T, Nennstiel P, Müller A. Isozyme selective inhibition of cGMPstimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine. Cell Signal 1995; 7: 733-738.
22. Raeburn D, UnderwoodL, LewisA, et al. Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor. Br J Pharmacol 1994; 113: 1423-1431.
23. Boess FG, Hendrix M, van der Staay FJ, et al. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 2004; 47: 1081-1092.
24. Lugnier C, Schoeffter P, Le Bec A, et al. Selective inhibition of cyclic nucleotide phosphdiesterases of human, bovine and rat aorta. Biochem Pharmacol 1986; 35: 1743-1751.
25. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
26. Keravis T, Thaseldar-Roumié R, Lugnier C. Assessment of phosphodiesterase isozyme contribution in cell and tissue extracts. Methods Mol Biol 2005; 307: 63-74.
27. Campos-Toimil M, Keravis T, Orallo F, et al. Short-term and long-term treatments with a phosphodiesterase-4 (PDE4) inhibitor result in opposing agonistinduced Ca2+ responses in endothelial cells. Br J Pharmacol 2008; 154: 82-92.
28. Keravis T, Silva AP, Favot L, et al. Role of PDEs in vascular healty and disease: endothelial PDEs and angiogenesis. In: Cyclic Nucleotide Phosphodiesterases in Health and Disease. CRC, 2006; pp. 417-439.
29. Lugnier C, Schini VB. Characterisation of cyclic nucleotide phosphodiesterases from cultured bovine aortic endothelial cells. Biochem Pharmacol 1990; 39: 75-84.
30. Souness JE, Diocee BK, Martin W, et al. Pig aortic endothelial-cell cyclic nucleotide phosphodiesterases. Use of phosphodiesterase inhibitors to evaluate their roles in regulating cyclic nucleotide levels in intact cells. Biochem J 1990; 266: 127-32.
31. Netherton SJ, Maurice DH. Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis. Mol Pharmacol 2005; 67: 263-272.
32. Favot L, Martin S, Keravis T, et al. Involvement of cyclin-dependent pathway in the inhibitory effect of delphinidin on angiogenesis. Cardiovasc Res 2003; 59: 479-487.
33. Alvarez E, Justiniano-Basaran H, Lugnier C, et al. Study of the mechanisms involved in the vasorelaxation induced by (-)-epigallocatechin-3-gallate in rat aorta. Br J Pharmacol 2006; 147: 269-280.
34. Yarwood SJ, Steele MR, Scotland G, et al. The RACK1 signalling scaffold protein selectively interacts with the cAMP-specific phosphodiesterase PDE4D5 isoform. J Biol Chem 1999; 274: 14909-14917.
35. Dodge KL, Khouangsathiene S, Kapiloff MS, et al. 2001. mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signalling module. EMBO J 2001; 20: 1921-1930.
36. Brunton LL. PDE4: arrested at the border. Sci STKE 2003; 204: PE44.
37. Georget M, Mateo P, Vandecasteele G, et al. Cyclic AMP compartmentation due to increased cAMP-phosphodiesterase activity in transgenic mice with a cardiac-directed expression of the human adenylyl cyclase type 8 (AC8). FASEB J 2003; 17: 1380-1391.
38. Maurice DH. Subcellular signalling in the endothelium: cyclic nucleotides take their place. Curr Opin Pharmacol 2011; 11: 656-664.
39. Lugnier C, Keravis T, Le Bec A et al. 1999. Characterisation of cyclic nucleotide phosphodiesterase isoforms associated to isolated cardiac nuclei. Biochim Biophys Acta 1999; 1472: 431-446.
40. Seybold J, Thomas D, Witzenrath M, et al. Tumour necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability. Blood 2005; 105: 3569-3576.
41. Rampersad SN, Ovens JD, Huston E, et al. Cyclic AMP phosphodiesterase 4D (PDE4D) Tethers EPAC1 in a vascular endothelial cadherin (VE-Cad)-based signalling complex and controls cAMP-mediated vascular permeability. J Biol Chem 2010; 285: 33614-33622.
42. Geoffroy V, Fouque F, Nivet V, et al. Activation of a cGMP-stimulated cAMP phosphodiesterase by protein kinase C in a liver Golgi-endosomal fraction. Eur J Biochem 1999; 259: 892-900.
43. Xu H, Czerwinski P, Hortmann M, et al. Protein kinase C alpha promotes angiogenic activity of human endothelial cells via induction of vascular endothelial growth factor. Cardiovasc Res 2008; 78: 349-355.
44. Diebold I, Djordjevic T, Petry, A, et al. Phosphodiesterase 2 mediates redox-sensitive endothelial cell proliferation and angiogenesis by thrombin via Rac1 and NADPH oxidase 2. Circ Res. 2009; 104: 1169-1177.